Clinical Trial Update: Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and immunogenicity of the ChimeriVax-WN02 West Nile vaccine in healthy adults, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• West Nile Fever

Drugs mentioned

• ChimeriVax-WN02 West Nile Vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: West Nile Fever | Phase 2 | Status: COMPLETED | Results posted: 2011-02-14